【NEWS】Signing ceremony for MoU between Cyto-Facto Inc. and Thermo Fisher Scientific Japan
2024/12/04
We are pleased to announce that Cyto-Facto Inc. has signed a Memorandum of Understanding (MoU) with Thermo Fisher Scientific Japan to cooperate on process development for the manufacture of viral vectors for clinical applications. The signing ceremony was held on November 20, 2024 at the Kobe Medical Innovation Center (KCMI). This new partnership is aimed at developing processes for suspension-based scale up of viral vectors in single-use bioreactors to expedite the provision of clinical-grade viral vectors for gene therapies.
Through this new partnership, we will establish a viral vector production platform and contribute to the realization of a society that can deliver innovative treatments to patients in need of gene therapy.
For further inquiries, please contact our communications team at info@cytofacto.com.
